Targeting the proteasome: Partial inhibition of the proteasome by bortezomib or deletion of the immunosubunit LMP7 attenuates experimental colitis

Gut

Volumn 59, Issue 7, 2010, Pages 896-906

  Schmidt, Nicole ^a   Gonzalez, Erik ^a   Visekruna, Alexander ^b   Kühl, Anja A ^c   Loddenkemper, Christoph ^c   Mollenkopf, Hans ^a   Kaufmann, Stefan H E ^a   Steinhoff, Ulrich ^a   Joeris, Thorsten ^a  

^a MAX PLANCK INSTITUTE FOR INFECTION BIOLOGY   (Germany)

^b PHILIPPS UNIVERSITY MARBURG   (Germany)

^c CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BORTEZOMIB; CHEMOKINE; CYTOKINE; DEXTRAN SULFATE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PROTEASOME;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; COLITIS; CYTOKINE RELEASE; DOSE RESPONSE; DRUG EFFECT; DRUG MEGADOSE; EMBRYO; FEMALE; GENE; IMMUNOCOMPETENT CELL; INFLAMMATION; LMP7 GENE; LOW DRUG DOSE; MORTALITY; MOUSE; NEUTROPHIL CHEMOTAXIS; NONHUMAN; PRIORITY JOURNAL; T LYMPHOCYTE; TH1 CELL; TH17 CELL; TISSUE INJURY;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; BORONIC ACIDS; COLITIS; DEXTRAN SULFATE; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG EVALUATION, PRECLINICAL; FEMALE; IMMUNITY, MUCOSAL; INFLAMMATION MEDIATORS; INTERLEUKIN-17; MICE; MICE, INBRED C57BL; MULTIENZYME COMPLEXES; NEUTROPHIL INFILTRATION; NF-KAPPA B; PROTEASE INHIBITORS; PROTEASOME ENDOPEPTIDASE COMPLEX; PYRAZINES; SIGNAL TRANSDUCTION; T-LYMPHOCYTE SUBSETS; TH1 CELLS;

EID: 77954008149     PISSN: 00175749     EISSN: 14683288     Source Type: Journal    
DOI: 10.1136/gut.2009.203554     Document Type: Article

References (38)

1. Bouma G, Strober W. The immunological and genetic basis of inflammatory bowel disease. Nat Rev Immunol 2003;3:521-33.
2. Strober W, Fuss I, Mannon P. The fundamental basis of inflammatory bowel disease. J Clin Invest 2007;117:514-21.
3. Bonizzi G, Karin M. The two NF-kappaB activation pathways and their role in innate and adaptive immunity. Trends Immunol 2004;25:280-8.
4. Schreiber S, Nikolaus S, Hampe J. Activation of nuclear factor kappa B inflammatory bowel disease. Gut 1998;42:477-84. (Pubitemid 28186562)
5. Alkalay I, Yaron A, Hatzubai A, et al. Stimulation-dependent I kappa B alpha phosphorylation marks the NF-kappa B inhibitor for degradation via the ubiquitin-proteasome pathway. Proc Natl Acad Sci USA 1995;92:10599-603.
6. Alvarez-Castelao B, Castano JG. Mechanism of direct degradation of IkappaBalpha by 20S proteasome. FEBS Lett 2005;579:4797-802.
7. Moorthy AK, Savinova OV, Ho JQ, et al. The 20S proteasome processes NF-kappaB1, p105 into, p50 in a translation-independent manner. EMBO J 2006;25:1945-56.
8. Palombella VJ, Rando OJ, Goldberg AL, et al. The ubiquitin - proteasome pathway is required for processing the NF-kappa B1 precursor protein and the activation of NF-kappa B. Cell 1994;78:773-85.
9. Traenckner EB, Wilk S, Baeuerle PA. A proteasome inhibitor prevents activation of NF-kappa B and stabilizes a newly phosphorylated form of I kappa B-alpha that is still bound to NF-kappa B. EMBO J 1994;13:5433-41.
10. Coux O, Tanaka K, Goldberg AL. Structure and functions of the 20S and 26S proteasomes. Annu Rev Biochem 1996;65:801-47. (Pubitemid 26255262)
11. Groettrup M, Khan S, Schwarz K, et al. Interferon-gamma inducible exchanges of 20S proteasome active site subunits: why? Biochimie 2001;83:367-72.
12. Visekruna A, Joeris T, Schmidt N, et al. Comparative expression analysis and characterization of 20S proteasomes in human intestinal tissues: the proteasome pattern as diagnostic tool for IBD patients. Inflamm Bowel Dis 2009;15:526-33.
13. Visekruna A, Joeris T, Seidel D, et al. Proteasome-mediated degradation of IkappaBalpha and processing of p105 in Crohn disease and ulcerative colitis. J Clin Invest 2006;116:3195-203.
14. Griffin TA, Nandi D, Cruz M, et al. Immunoproteasome assembly: cooperative incorporation of interferon gamma (IFN-gamma)-inducible subunits. J Exp Med 1998;187:97-104.
15. Heink S, Ludwig D, Kloetzel PM, et al. IFN-gamma-induced immune adaptation of the proteasome system is an accelerated and transient response. Proc Natl Acad Sci USA 2005;102:9241-6.
16. Conner EM, Brand S, Davis JM, et al. Proteasome inhibition attenuates nitric oxide synthase expression, VCAM-1 transcription and the development of chronic colitis. J Pharmacol Exp Ther 1997;282:1615-22.
17. Fissolo N, Kraus M, Reich M, et al. Dual inhibition of proteasomal and lysosomal proteolysis ameliorates autoimmune central nervous system inflammation. Eur J Immunol 2008;38:2401-11.
18. Inoue S, Nakase H, Matsuura M, et al. The effect of proteasome inhibitor MG132 on experimental inflammatory bowel disease. Clin Exp Immunol 2009;156:172-82.
19. Sinn DI, Lee ST, Chu K, et al. Proteasomal inhibition in intracerebral hemorrhage: neuroprotective and anti-inflammatory effects of bortezomib. Neurosci Res 2007;58:12-18. (Pubitemid 46695794)
20. Fehling HJ, Swat W, Laplace C, et al. MHC class I expression in mice lacking the proteasome subunit LMP-7. Science 1994;265:1234-7. (Pubitemid 24291982)
21. Hoffmann A, Levchenko A, Scott ML, et al. The IkappaB-NF-kappaB signaling module: temporal control and selective gene activation. Science 2002;298:1241-5.
22. Foell D, Wittkowski H, Roth J. Monitoring disease activity by stool analyses: from occult blood to molecular markers of intestinal inflammation and damage. Gut 2009;58:859-68.
23. Melgar S, Karlsson A, Michaelsson E. Acute colitis induced by dextran sulphate sodium progresses to chronicity in C57BL/6 but not in BALB/c mice: correlation between symptoms and inflammation. Am J Physiol Gastrointest Liver Physiol 2005;288:G1328-38.
24. Nenci A, Becker C, Wullaert A, et al. Epithelial NEMO links innate immunity to chronic intestinal inflammation. Nature 2007;446:557-61.
25. Zaph C, Troy AE, Taylor BC, et al. Epithelial-cell-intrinsic IKK-beta expression regulates intestinal immune homeostasis. Nature 2007;446:552-6.
26. Kuhl AA, Kakirman H, Janotta M, et al. Aggravation of different types of experimental colitis by depletion or adhesion blockade of neutrophils. Gastroenterology 2007;133:1882-92.
27. Buanne P, Di Carlo E, Caputi L, et al. Crucial pathophysiological role of CXCR2 in experimental ulcerative colitis in mice. J Leukoc Biol 2007;82:1239-46.
28. Kwon JH, Keates AC, Anton PM, et al. Topical antisense oligonucleotide therapy against LIX, an enterocyte-expressed CXC chemokine, reduces murine colitis. Am J Physiol Gastrointest Liver Physiol 2005;289:G1075-83.
29. Shea-Donohue T, Thomas K, Cody MJ, et al. Mice deficient in the CXCR2 ligand, CXCL1 (KC/GRO-alpha), exhibit increased susceptibility to dextran sodium sulfate (DSS)-induced colitis. Innate Immun 2008;14:117-24.
30. Castaneda FE, Walia B, Vijay-Kumar M, et al. Targeted deletion of metalloproteinase 9 attenuates experimental colitis in mice: central role of epithelial-derived MMP. Gastroenterology 2005;129:1991-2008.
31. Kobayashi K, Arimura Y, Goto A, et al. Therapeutic implications of the specific inhibition of causative matrix metalloproteinases in experimental colitis induced by dextran sulphate sodium. J Pathol 2006;209:376-83.
32. Krieglstein CF, Cerwinka WH, Laroux FS, et al. Regulation of murine intestinal inflammation by reactive metabolites of oxygen and nitrogen: divergent roles of superoxide and nitric oxide. J Exp Med 2001;194:1207-18.
33. Nussbaum AK, Rodriguez-Carreno MP, Benning N, et al. Immunoproteasome- deficient mice mount largely normal CD8+ T cell responses to lymphocytic choriomeningitis virus infection and DNA vaccination. J Immunol 2005;175:1153-60. (Pubitemid 41095002)
34. Strehl B, Joeris T, Rieger M, et al. Immunoproteasomes are essential for clearance of Listeria monocytogenes in nonlymphoid tissues but not for induction of bacteria-specific CD8+ T cells. J Immunol 2006;177: 6238-44.
35. Busse A, Kraus M, Na IK, et al. Sensitivity of tumor cells to proteasome inhibitors is associated with expression levels and composition of proteasome subunits. Cancer 2008;112:659-70.
36. Drews O, Wildgruber R, Zong C, et al. Mammalian proteasome subpopulations with distinct molecular compositions and proteolytic activities. Mol Cell Proteomics 2007;6:2021-31.
37. Klare N, Seeger M, Janek K, et al. Intermediate-type 20S proteasomes in HeLa cells: "asymmetric" subunit composition, diversity and adaptation. J Mol Biol 2007;373:1-10.
38. Xavier RJ, Podolsky DK. Unravelling the pathogenesis of inflammatory bowel disease. Nature 2007;448:427-34.